Grantvello Find funders

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Open

National Institutes of Health · Opportunity number PAR-28-042

PostedNov 3, 2026
Closing dateNov 16, 2029
Award ceilingNot listed
Expected awardsNot listed
From Grants.gov

Eligibility

Nonprofits are listed as eligible applicants.

  • For profit organizations other than small businesses
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Public and state controlled institutions of higher education
  • County governments
  • City or township governments
  • Special district governments
  • State governments
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Private institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities/Indian housing authorities
  • Small businesses
  • Independent school districts

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Description

The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.

Funding

Total program fundingNot listed
Award floorNot listed
Award ceilingNot listed
CategoryHealth
Assistance listing93.CA1

Official sources

Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.